# BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

> **NCT06205706** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **BioInvent International AB** · enrollment: 35 (actual)

## Conditions studied

- Solid Tumors
- Non Small Cell Lung Cancer
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** BI-1910
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06205706
- **Lead sponsor:** BioInvent International AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-04
- **Primary completion:** 2027-07-14
- **Final completion:** 2028-11-07
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06205706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06205706, "BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06205706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*